他汀类药物降低颈动脉支架置入术后死亡率和抢救失败率
基于Premier医疗数据库2009至2015年17800例颈动脉支架置入术患者的回顾性分析,其中12416例(70%)使用他汀。校正混杂因素后,他汀与死亡风险降低64%相关(OR 0.36),卒中/死亡复合风险降低18%相关(OR 0.82);发生卒中或心梗者中,他汀组抢救失败率11.4% vs 非他汀组30.8%。
要点
- 他汀组术后死亡率1.0%,非他汀组1.8%(P < .001)。
- 校正后他汀与死亡风险降低64%相关(OR 0.36;95%CI 0.27-0.47;P < .001)。
- 发生卒中或心梗者中,他汀组抢救失败率11.4% vs 非他汀组30.8%(P < .001)。
核心结论
- 他汀使用与颈动脉支架置入术后发生主要并发症(卒中/心梗)患者死亡率和抢救失败率的显著降低相关。
- 作者结论认为,应强烈鼓励所有接受颈动脉支架置入术的患者使用他汀。
研究设计与样本
- 回顾性分析Premier医疗数据库,纳入2009至2015年所有接受颈动脉支架置入术的患者,共17800例,其中12416例(70%)使用他汀。
- 采用单变量(χ2检验、t检验)和多变量模型(逻辑回归)评估他汀对术后结局的影响。
主要发现
- 他汀组症状性患者比例高于非他汀组(41% vs 31%;P < .001),且高血压、糖尿病、冠心病、血脂异常、充血性心力衰竭史、卒中史、心肌梗死史及外周动脉疾病等合并症均显著更多(均P < .05)。
- 术后死亡率他汀组为1.0%,非他汀组为1.8%(P < .001)。
- 他汀使用对术后卒中风险无影响(OR 1.09;95%CI 0.88-1.34;P = .44),且与心肌梗死风险升高相关(OR 2.08;95%CI 1.26-3.45;P = .004)。
- 校正潜在混杂因素后,他汀与死亡风险降低64%相关(OR 0.36;95%CI 0.27-0.47;P < .001),与卒中/死亡复合风险降低18%相关(OR 0.82;95%CI 0.68-0.99;P = .03)。
- 在发生卒中或心肌梗死的患者中,他汀组抢救失败率(死亡率)显著低于非他汀组(11.4% vs 30.8%;P < .001)。
关键数值与推荐
- 他汀组 vs 非他汀组术后死亡率:1.0% vs 1.8%(P < .001)。
- 校正后他汀与死亡风险降低相关:OR 0.36(95%CI 0.27-0.47;P < .001)。
- 校正后他汀与卒中/死亡复合风险降低相关:OR 0.82(95%CI 0.68-0.99;P = .03)。
- 术后卒中风险:OR 1.09(95%CI 0.88-1.34;P = .44),无显著差异。
- 术后心肌梗死风险:OR 2.08(95%CI 1.26-3.45;P = .004)。
临床怎么用
- 作者结论建议应强烈鼓励所有接受颈动脉支架置入术的患者使用他汀。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The benefit of statins has been well established in reducing morbidities and mortality after carotid endarterectomy. However, the potential advantage of statin use in patients undergoing carotid artery stenting (CAS) remains largely unknown. The purpose of this study was to evaluate the effect of statins on postoperative outcomes after CAS. METHODS: The Premier Healthcare Database was retrospectively analyzed to identify all patients who underwent CAS from 2009 to 2015. Univariate (χ2 test, t-test) and multivariate models (logistic regression) were used to evaluate the effect of statins on postoperative outcomes. RESULTS: A total of 17,800 patients underwent CAS during the study period; 12,416 (70%) patients were taking statins. The statin group had more symptomatic patients (41% vs 31%; P < .001) and had significantly higher comorbidities including hypertension, diabetes, coronary artery disease, dyslipidemia, history of congestive heart failure, history of stroke, history of myocardial infarction (MI), and peripheral artery disease (all P < .05). Postoperative mortality was 1.0% vs 1.8% in the statin and nonstatin groups, respectively (P < .001). Statin use had no effect on odds of postoperative stroke (odds ratio [OR], 1.09; 95% confidence interval [CI], 0.88-1.34; P = .44) and higher odds of MI (OR, 2.08; 95% CI, 1.26-3.45; P = .004). After adjustment for potential confounders, statins were associated with 64% reduction in the odds of death (OR, 0.36; 95% CI, 0.27-0.47; P < .001) and 18% reduction in stroke/death (OR, 0.82; 95% CI, 0.68-0.99; P = .03). In patients who had a stroke or MI, statin users had significantly lower failure to rescue (lower mortality) compared with nonstatin users (11.4% vs 30.8%; P < .001). CONCLUSIONS: Statin use is associated with significant reduction in mortality and failure to rescue in patients who develop major complications (stroke/MI) after CAS. Therefore, statin use should be strongly encouraged in all patients undergoing CAS.
引用
- Rizwan M, Faateh M, Dakour-Aridi H, et al. Statins reduce mortality and failure to rescue after carotid artery stenting. J Vasc Surg. 2018. PMID: 29914834. doi:10.1016/j.jvs.2018.03.424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。